Rucaparib

Target: This ligand targets poly(ADP-ribose) polymerases PARP1 and PARP2 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for poly(ADP-ribose) polymerases PARP1 and PARP2. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings poly(ADP-ribose) polymerases PARP1 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PARP1-Directed PROTAC Degradation: Rucaparib can serve as a PARP1-targeting ligand within PROTAC constructs to recruit an E3 ubiquitin ligase and drive ubiquitination-dependent PARP1 removal. This application supports mechanistic studies of PARP1 degradation, including effects on DNA damage signaling, PARylation dynamics, and downstream repair pathway engagement.

• DNA Damage Response Remodeling: Using Rucaparib-based PROTACs enables controlled degradation of PARP1 to dissect how loss of PARP1 influences replication stress tolerance and DNA repair pathway choice. Researchers can evaluate changes in γH2AX formation, homologous recombination versus alternative end joining markers, and cell-cycle checkpoint activation under defined genotoxic conditions.

• E3 Ligase Recruitment Optimization: Rucaparib-derived PROTACs can be engineered with different E3 ligase-binding moieties to optimize ternary complex formation, ubiquitination efficiency, and degradation potency. This direction is valuable for mapping structure–activity relationships that govern target engagement duration and degradation selectivity across PARP family members.

• Resistance Mechanism Investigation: Rucaparib-directed PARP1 degradation can be used to probe resistance mechanisms that emerge under PARP inhibition. By comparing degradation-driven phenotypes with catalytic inhibition, studies can distinguish whether resistance is linked to altered PARP1 stability, compensatory pathway activation, or changes in ubiquitin–proteasome processing.

• Target Selectivity and Off-Target Profiling: Rucaparib-based PROTACs facilitate systematic evaluation of degradation selectivity by monitoring PARP1 loss relative to other PARP isoforms and DNA damage proteins. This application supports proteome-level and pathway-focused analyses to identify off-target degradation events and refine ligand design for improved specificity.

Rucaparib is a PARP target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Rucaparib is characterized by primary or secondary amine/basic nitrogen centers; halogenated aryl/heteroaryl ring system. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.